SightLine Partners
SightLine Partners is an investment firm based in Bloomington, Minnesota, with an additional office in Palo Alto, California. Founded in 2004, it concentrates on healthcare investments across the United States, including medical technology, medical devices, diagnostics, biotechnology, and healthcare services. The firm targets later-stage and growth opportunities, investing in private companies through preferred stock typically between $2 million and $8 million, with an expected exit within about five years. Its focus includes therapeutic areas such as vascular diseases, diabetes, neurology, cardiovascular and orthopedic care, oncology, and infectious disease, as well as senior care, home healthcare, specialty facilities, ancillary and alternate-site services, and healthcare outsourcing. The firm seeks US-based opportunities in late-stage and expansion ventures within healthcare, life sciences, and related sectors.
Top Stages
https://crunchbase.com/organization/***
https://linkedin.com/company/***
Past deals in Minnesota
Monteris Medical
Series C in 2017
Monteris Medical, Inc. is a medical device company specializing in the development and marketing of innovative technologies for the treatment of brain diseases. Founded in 1999 and based in Plymouth, Minnesota, with additional offices in Minneapolis and Winnipeg, the company focuses on minimally-invasive, MRI-guided, and robotically controlled neurosurgical procedures. Its flagship product, the NeuroBlate System, utilizes focused laser energy to safely ablate pathological brain lesions, such as tumors, while minimizing damage to surrounding healthy tissue. Monteris Medical also provides various stereotactic anchoring devices and stabilization systems for enhanced precision during image-guided procedures. The company markets its products directly to neurosurgeons in the United States, aiming to improve surgical outcomes through advanced technology.
Conventus Orthopaedics
Series A in 2014
Conventus Orthopaedics offers orthopedic and sports medicine services, including surgery, reconstructive procedures, spine surgery, joint replacement, sports medicine, physical therapy, and fracture care. Founded by medical professionals in 2009, the company focuses on less invasive treatments for complex periarticular fractures. It employs advanced nitinol technology to create a platform that delivers robust fixation and reliable repairs. The practice is located in Maple Grove, Minnesota.
Conventus Orthopaedics
Venture Round in 2013
Conventus Orthopaedics offers orthopedic and sports medicine services, including surgery, reconstructive procedures, spine surgery, joint replacement, sports medicine, physical therapy, and fracture care. Founded by medical professionals in 2009, the company focuses on less invasive treatments for complex periarticular fractures. It employs advanced nitinol technology to create a platform that delivers robust fixation and reliable repairs. The practice is located in Maple Grove, Minnesota.
CVRx
Series F in 2013
CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.
Celleration
Series E in 2011
Celleration Inc. is a privately held medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, utilizes low-frequency ultrasound delivered through a saline mist to promote healing in wounds. This innovative approach allows ultrasound energy to penetrate beyond the surface of the wound, stimulating cellular activity and enhancing the healing process. Since receiving FDA clearance in 2005, Celleration has established a strong presence in the U.S. market, with over 1 million MIST Therapy treatments performed, benefiting more than 65,000 patients across numerous healthcare facilities. Celleration's commitment to advancing wound care technology has resulted in significant clinical and economic benefits, reinforcing its role in the medical community.
CVRx
Series E in 2008
CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.
Atritech
Series D in 2007
Atritech is a private medical technology company based in Minneapolis, Minnesota, founded in 2000. The company specializes in developing minimally invasive technologies aimed at preventing strokes related to atrial fibrillation. Their flagship product, the WATCHMAN Left Atrial Appendage Closure Technology, is designed to offer a permanent alternative to long-term anticoagulation therapy for patients with non-valvular atrial fibrillation who are at risk of stroke. The device works by closing off the left atrial appendage, preventing harmful blood clots from entering the bloodstream and causing strokes or other complications. The WATCHMAN Device has been CE Marked and is available in many markets outside the United States, while it is currently under investigation in the U.S.
CVRx
Series D in 2007
CVRx develops and markets implantable neuro-modulation therapies for treating high blood pressure and heart failure. Its flagship product, BAROSTIM NEO, triggers the body's natural reflex to regulate blood pressure, slowing heart failure progression. CVRx serves patients and healthcare professionals worldwide.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.